Comparative Efficacy of Dys-Fizz Tablet and Hinguvachadi Churna in Managing Udavartini Yonivyapad

A randomized controlled clinical study to compare the efficacy of dys-fizz tablet with hinguvachadi churna in the management of udavartini yonivyapad - NILL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084874

Enrollment

Registered

2025-04-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N946- Dysmenorrhea, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed patients of Udavartini Yonivyapad ( Patients suffering from dysmenorrhea). Patients suffering from dysmenorrhea for the past 3 or more consecutive cycles.

Exclusion criteria

Exclusion criteria: Age below 18years and above 40 years. Patient coming with chief complaints of painful menstruation with regular. Females with irregular menstrual cycle. Patients having congenital anomalies leading to dysmenorrhea. Patient with IUD /oral contraceptives.

Design outcomes

Primary

Measure	Time frame
DYS-FIZZ tablet is more effective than hinguvachadi choorna in management of udavartini yonivyapadTimepoint: BT- 0th Day DT- 4th Day of 1st and 2nd cycle of Menstruation AT- 12th Week Treatment Duration- 1st 6days of expected munstruation date and 2days of menses for 2cycle Assesment on 4th Day of menses Final Assesment on 12th week	—

Secondary

Measure	Time frame
Hinguvachadi choorna is equal effective as DYS-FIZZ tablet in udavartini yonivyapadTimepoint: BT- 0th Day DT- 4th Day of 1st & 2nd cycle of Menstruation AT- 12th Week Treatment Duration- 1st 6days of expected munstruation date & 2days of menses for 2cycle Assesment on 4th Day of menses Final Assesment on 12th week	—

Countries

India

Contacts

Public ContactDr Divya Shingare

Parul Institute of Ayurved and Research

abharavi22@gmail.com8281578252

Outcome results